Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) ar

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the pr

Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.07 per share versus the Zacks C

Castle Biosciences NASDAQ: CSTL reported second-quarter 2026 revenue of $103.5 million, up 20% from

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $345.000 million-$355.000 million

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.07) per share which beat the analy

FRIENDSWOOD, Texas, July 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company

Approval expands access to Castle's precision medicine test designed to guide systemic treatment dec

FRIENDSWOOD, Texas, July 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurate

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately i

Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s

Roth Capital analyst Max Masucci initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Bu

Stokes was one of 22 financial leaders recognized in the Greater Houston area FRIENDSWOOD, Texas, Ju

FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company

STOCKHOLM, June 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading devel

FRIENDSWOOD, Texas, May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the pr

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing so

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and l

Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.49 per share versus the Zacks C

Castle Biosciences (NASDAQ:CSTL) raises FY2026 sales outlook from $340.000 million-$350.000 million

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.49) per share which met the analys

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (

The mean of analysts' price targets for Castle Biosciences (CSTL) points to an 85.2% upside in the s

Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved ri

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologicall

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologicall

Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and l

Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Me

Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that gui

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and r

Castle Biosciences (NASDAQ:CSTL) sees FY2026 sales of $340.000 million-$350.000 million vs $333.778

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.08) per share which beat the analy

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that gui

Guggenheim analyst Subbu Nambi maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises t

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raise